|
Name |
Institution |
Position/Area of expertise/interest |
|
Professor Aras Kadioglu (Chairman) |
University of Liverpool |
Professor of Bacterial Pathogenesis Immunology/Pneumococcal pathogenesis |
|
Prof Andrew Pettitt |
University of Liverpool |
Professor of Haematology, Molecular and Clinical Medicine. Lead for clinical and translational research. Honorary Consultant Royal Liverpool Hospital Clinical research interests in national trials/industry collaboration Laboratory research programme is focussed on the development of clinically useful biomarkers and elucidation of drug action and resistance mechanisms |
|
Prof Christopher Twelves
|
Leeds University |
Professor of Clinical Cancer Pharmacology and Oncology Clinical oncology interests = colorectal and breast cancer/Experimental drug development |
|
Dr Nikki Copeland |
Lancaster University |
Lecturer in Biomedicine DNA replication/Chromosomal aberrations |
|
Dr Joe Sacco |
University of Liverpool |
Consultant in Medical Oncology/Molecular and Clinical Medicine Melanoma/Head and Neck Cancer/ Deubiquitylating |
|
Dr Jessica Okosun |
Barts Cancer Institute, Queen Mary University of London |
Position: Clinical Senior Lecturer and Honorary Consultant Haematologist Areas of expertise/interest: Molecular pathogenesis of lymphomas. Genomics. Cancer heterogeneity and evolution. Big Data analyses. Development of molecular biomarkers |
|
Dr Tania Seale |
North West Cancer Research |
Research Manager NWCR. Academic mixed methods researcher in the area of early diagnosis of cancer. NHS clinical cancer researcher and health care professional. |
|
Dr Michela Garofalo |
Junior Group Leader, CRUK, University of Manchester |
"The main goal of my research is to contribute to the better understanding of the functions of non-coding RNAs in lung cancer progression and explore how cancer cells hijack non-coding RNA expression to maintain their malignant phenotype. This should bring to the identification of cancer vulnerabilities that will be targeted with novel pharmacological approaches to produce a less toxic and long-lasting response in patients." |
|
Prof Martin Dyer |
University of Leicester |
Immunologist |
|
Prof Chris Pepper |
University of Sussex |
Immunologist |
|
Dr John Marshall |
PPI |
Lay member |
|
De Esther Baena |
CRUK Manchester University |
Prostate oncobiology |